Can you take Arcapta with Vimseltinib?

Vimseltinib has a moderate potential interaction with Biliary Obstruction.

Vimseltinib should be avoided in patients with preexisting increased serum transaminases; total bilirubin or direct bilirubin (greater than 1 times the upper limit of normal [1 x ULN]); or active liver or biliary tract disease, including alkaline phosphatase. Liver tests (including AST, ALT, total bilirubin, direct bilirubin, alkaline phosphatase, and GGT) should be monitored before starting vimseltinib, twice a month for the first 2 months of therapy, every 3 months for the first year of therapy, and as clinically indicated thereafter. Vimseltinib has not been studied in patients with moderate (bilirubin greater than 1.5 to 3 x ULN and any AST) or severe (bilirubin greater than 3 x ULN and any AST) liver dysfunction. No dose adjustment is recommended for patients with mild (bilirubin up to 1 x ULN and AST greater than 1 x ULN or bilirubin greater than 1 to 1.5 x ULN and any AST) liver dysfunction.

The indacaterol in Arcapta has a moderate potential interaction with Diabetes Mellitus.

Adrenergic bronchodilators may cause increases in blood glucose concentrations. These effects are usually transient and slight, but may be significant with dosages higher than those normally recommended. Large doses of IV albuterol (not commercially available in the U.S.) and terbutaline sulfate have been reported to cause exacerbation of preexisting diabetes mellitus and ketoacidosis. Therapy with adrenergic bronchodilators should be administered cautiously in patients with diabetes mellitus. Closer monitoring of blood glucose concentrations may be appropriate. Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.

The indacaterol in Arcapta has a moderate potential interaction with Heart Disease.

Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression). Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol. However, beta-2-selectivity is not absolute and can be lost with larger doses. High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias. Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and/or underlying cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension. The recommended dosages should not be exceeded.

The indacaterol in Arcapta has a moderate potential interaction with High Blood Pressure.

Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression). Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol. However, beta-2-selectivity is not absolute and can be lost with larger doses. High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias. Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and/or underlying cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension. The recommended dosages should not be exceeded.

Vimseltinib has a moderate potential interaction with Hyperbilirubinemia.

Vimseltinib should be avoided in patients with preexisting increased serum transaminases; total bilirubin or direct bilirubin (greater than 1 times the upper limit of normal [1 x ULN]); or active liver or biliary tract disease, including alkaline phosphatase. Liver tests (including AST, ALT, total bilirubin, direct bilirubin, alkaline phosphatase, and GGT) should be monitored before starting vimseltinib, twice a month for the first 2 months of therapy, every 3 months for the first year of therapy, and as clinically indicated thereafter. Vimseltinib has not been studied in patients with moderate (bilirubin greater than 1.5 to 3 x ULN and any AST) or severe (bilirubin greater than 3 x ULN and any AST) liver dysfunction. No dose adjustment is recommended for patients with mild (bilirubin up to 1 x ULN and AST greater than 1 x ULN or bilirubin greater than 1 to 1.5 x ULN and any AST) liver dysfunction.

The indacaterol in Arcapta has a moderate potential interaction with Hyperthyroidism.

Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression). Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol. However, beta-2-selectivity is not absolute and can be lost with larger doses. High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias. Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and/or underlying cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension. The recommended dosages should not be exceeded.

The indacaterol in Arcapta has a moderate potential interaction with Hypokalemia.

Adrenergic bronchodilators may cause decreases in serum potassium concentrations, primarily when given by nebulization or intravenous administration. Although this effect is usually transient and does not require supplementation, clinically significant hypokalemia may occur in some patients, with the potential to induce cardiovascular adverse effects. The relevance of these observations to oral or oral aerosol/powder for inhalation therapy is unknown. Therapy with adrenergic bronchodilators should be administered cautiously in patients with or predisposed to hypokalemia.

Vimseltinib has a moderate potential interaction with Liver Disease.

Vimseltinib should be avoided in patients with preexisting increased serum transaminases; total bilirubin or direct bilirubin (greater than 1 times the upper limit of normal [1 x ULN]); or active liver or biliary tract disease, including alkaline phosphatase. Liver tests (including AST, ALT, total bilirubin, direct bilirubin, alkaline phosphatase, and GGT) should be monitored before starting vimseltinib, twice a month for the first 2 months of therapy, every 3 months for the first year of therapy, and as clinically indicated thereafter. Vimseltinib has not been studied in patients with moderate (bilirubin greater than 1.5 to 3 x ULN and any AST) or severe (bilirubin greater than 3 x ULN and any AST) liver dysfunction. No dose adjustment is recommended for patients with mild (bilirubin up to 1 x ULN and AST greater than 1 x ULN or bilirubin greater than 1 to 1.5 x ULN and any AST) liver dysfunction.

Vimseltinib has a moderate potential interaction with Renal Dysfunction.

During vimseltinib treatment, renal function should be assessed using alternative measures that are not based on serum creatinine. In 1 study, serum creatinine increased by a mean of 19 mcmol/L compared to baseline. These increases in serum creatinine may not be associated with changes in renal function but may be due to inhibition of renal tubular secretion transporters. Creatinine increases reversed when vimseltinib was discontinued. The effect of severe renal dysfunction (estimated GFR less than 30 mL/min) on vimseltinib pharmacokinetics is unknown.

The indacaterol in Arcapta has a moderate potential interaction with Seizures.

Adrenergic bronchodilators may cause CNS stimulation. Therapy with adrenergic bronchodilators should be administered cautiously in patients with seizure disorders. Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.